We use cookies to deliver our online services. Details of the cookies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you agree to our use of cookies. To close this message click close.

FDA Revises Forms for Submission of Patent Information to the Orange Book: Federal Circuit Decision in <i>Novartis AG v. Lee</i> Alters Patent Term Adjustment

26 February 2014

Pharmaceutical and Biotechnology Alert

Two recent developments will affect the listing of patent information with pharmaceutical products approved by the U.S. Food and Drug Administration (FDA). First, the FDA has revised the forms on which such information is submitted. The revised forms may alter the manner in which sponsors describe patent claims covering methods of using their FDA-approved drug products. Second, the Federal Circuit recently held that the U.S. Patent and Trademark Office (PTO) has incorrectly interpreted a statutory patent term adjustment under 35 USC 154 for certain patents whose prosecution included a request for continued examination.

Read More: FDA Revises Forms for Submission of Patent Information to the Orange Book: Federal Circuit Decision in Novartis AG v. Lee Alters Patent Term Adjustment

The team

Loading data